Table 1 Demographic and clinical information of the study patients
Patient | Age/Sex | Underlying Disease(s) | Drug Type and Duration | Stage/Location | Trigger Factor |
|---|---|---|---|---|---|
1 | 85/F | Hypertension, osteoporosis | PO, risedronate 2017–2021 | II/Mn Rt | Extraction |
2 | 83/F | Hypertension, diabetes, osteoporosis | PO, ibandronate 2010–2020; SC, denosumab 2020–2021 | II/Mn Rt | Extraction |
3 | 81/F | Multiple myeloma | IV, zoledronic Acid 2020–2021 | III/Mx Rt | Periodontitis |
4 | 90/F | Osteoporosis | PO, ibandronate 2000–2010; IV, ibandronate 2011–2021 | II/Mn Rt | Extraction |
5 | 83/F | Hypertension, osteoporosis | PO, ibandronate 2016–2019; IV, ibandronate 2019 ~ 2021 | II/Mx Rt | Extraction |
6 | 80/F | Hypertension, diabetes, osteoporosis | PO, alendronate 2017–2022 | II/Mn Rt | Implantation |
7 | 88/F | Hypertension, osteoporosis | PO, alendronate 2016 ~ 2021 | II/Mn Rt | Periodontitis |
8 | 86/F | Hypertension, angina, osteoporosis | IV, pamidronate 2013–2022 | II/Mn Lt | Extraction |
9 | 87/F | Arrhythmia, osteoporosis | PO, ibandronate 2011–2013; PO, risedronate 2013–2018; PO, ibandronate 2019–2020; SC, denosumab 2021–2022 | II/Mn Lt | Extraction |
10 | 72/F | Osteoporosis | IV, zoledronate 2017–2021 | II/Mn Lt | Extraction |
11 | 72/F | Osteoporosis | SC, denosumab 2020–2022 | III/Mx Lt | Periodontitis |
12 | 85/F | Osteoporosis | IV, pamidronate 2017–2021 | III/Mn Rt | Extraction |